Abstract
We report the discovery and hit-to-lead optimization of a structurally novel indazole series of CYP11B2 inhibitors. Benchmark compound 34 from this series displays potent inhibition of CYP11B2, high selectivity versus related steroidal and hepatic CYP targets, and lead-like physical and pharmacokinetic properties. On the basis of these and other data, the indazole series was progressed to lead optimization for further refinement.
Keywords:
Aldosterone synthase; CYP11B2; Hit-to-lead; Hypertension; Indazole.
Copyright © 2017 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Antihypertensive Agents / chemical synthesis
-
Antihypertensive Agents / pharmacokinetics
-
Antihypertensive Agents / pharmacology*
-
Aromatase Inhibitors / chemical synthesis
-
Aromatase Inhibitors / pharmacokinetics
-
Aromatase Inhibitors / pharmacology
-
Cell Line
-
Cricetulus
-
Cytochrome P-450 CYP11B2 / antagonists & inhibitors*
-
Cytochrome P-450 CYP2D6 Inhibitors / chemical synthesis
-
Cytochrome P-450 CYP2D6 Inhibitors / pharmacokinetics
-
Cytochrome P-450 CYP2D6 Inhibitors / pharmacology
-
Humans
-
Hypertension / drug therapy*
-
Indazoles / chemical synthesis
-
Indazoles / pharmacokinetics
-
Indazoles / pharmacology*
-
Macaca mulatta
-
Male
-
Rats, Sprague-Dawley
-
Stereoisomerism
-
Steroid 11-beta-Hydroxylase / antagonists & inhibitors
Substances
-
1,1,1-trifluoro-2-(5-(4-(trifluoromethyl)-1H-indazol-1-yl)pyridin-3-yl)propan-2-ol
-
Antihypertensive Agents
-
Aromatase Inhibitors
-
Cytochrome P-450 CYP2D6 Inhibitors
-
Indazoles
-
Cytochrome P-450 CYP11B2
-
Steroid 11-beta-Hydroxylase